glp-1 r retatrutide Retatrutide, a GIP, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide (LY3437943) | GCGR/GLP-1R/GIPR Agonist

Patients with complex medical histories, unexplained symptoms, pregnancy considerations, immune disorders, active cancer concerns, severe allergies, medication interactions, or competitive sport obligations should avoid self-directed use and seek medical guidance

If someone offers to prescribe based solely on a questionnaire with no physician review, find a different provider

Are GLP-1 drugs approved for autoimmune disease

GLP-1 causes the body to produce more insulin, which is key to reducing glucose levels in the blood

GLP-1 drugs don't work for everyone

In the past six months, the agency stated it has sent thousands of letters to pharmaceutical and telehealth companies directing them to remove misleading advertisements, more than had been sent over the entire preceding decade